Navigation Links
Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
Date:2/11/2009

-- Portola to Receive $75 Million Upfront Cash Payment, $500 Million in Potential Milestone Payments Plus Royalties on Future Sales --

SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced an exclusive worldwide license agreement with Novartis to develop and commercialize elinogrel, Portola's novel, proprietary intravenous (i.v.) and oral P2Y12 ADP receptor antagonist currently in Phase 2 clinical development. Elinogrel has shown potential to offer clinical improvements over current anti-clotting medications in helping patients avoid heart attacks and strokes.

Under terms of the agreement, Novartis will make an upfront cash payment to Portola of $75 million. Portola is eligible to receive additional cash payments totaling up to $500 million upon achievement of certain development, regulatory and commercialization milestones. Portola will also receive royalties on worldwide net sales of elinogrel. In addition, Portola has an option to co-promote elinogrel in the United States limited to hospitals and specialty markets.

Novartis will fund all future Phase 3 clinical trials of elinogrel and share costs of ongoing and planned Phase 2 trials. The agreement also provides Portola with an option to co-fund Phase 3 clinical trials and other development activities in return for additional royalties. The agreement is subject to review by the U.S. government under the Hart-Scott-Rodino Act and becomes effective after the expiration or earlier termination of the waiting period (or any extension thereof).

"Novartis is a global leader in cardiovascular drug development and marketing, which makes it an ideal partner to help us achieve elinogrel's therapeutic and market potential," said Charles Ho
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 ... ... 2015 Warrior-Family Symposium (WFS), cosponsored by the Military Officers Association of America ... the event, "Our Nation's Military: Caring For Our Own,” expert panelists will ...
(Date:9/2/2015)... Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... to expand their fleet of truly superb luxury vehicles based on which of the ... pleased to announce the latest step forward in pursuit of this goal: a 2015 ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Blincyto® (blinatumomab) – in the news recently following a decision by the Centers ... patients – is likely to average approximately $71,000 or roughly 40% of its ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... data collection, cloud analytics and workflow solutions today announced the September 2015 ... researchers to participate in interactive programs in which ERT scientists and partner ...
(Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... ... Internet of Things, announces its latest addition to its screen mirroring and extending ... award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, the new ...
Breaking Medicine News(10 mins):Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 2Health News:MOAA and WWP host 2015 Warrior-Family Symposium Chairman of the Senate Committee on Veterans' Affairs and the Secretary of Veterans Affairs to Speak 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3
... over 55 use colonoscopies for early detection of cancer, ... the costs since 2002. This was shown by an ... current edition of Deutsches rzteblatt International (Dtsch ... , The authors evaluated 245 263 colonoscopies performed ...
... of the highest rates, international survey finds , , TUESDAY, ... of the highest lifetime rates of tobacco and alcohol use ... or cocaine at least once in their lives, a new ... alcohol, tobacco and illegal drug use in 17 countries in ...
... following is a,statement by Christine James-Brown, President and CEO, ... the authority and opportunity,to delay the Medicaid Rehabilitative Services ... other controversial rules by including a,moratorium on them in ... a made a loud and clear statement that it ...
... Through ... Commercialization, LOS ANGELES, July 1 ... has appointed Denis A. O,Connor,as Chief Executive Officer of the company ... O,Connor has held senior,management positions at Philips Medical Systems, Sony Medical ...
... the only medical liability insurance company operating in Ohio that is ... will make its first cash distribution to its policyholders. This action ... outstanding loss results for the 2004 and 2005 policy years, closing ... ...
... HOUSTON, July 1 Millar Instruments, Inc. ... and,pressure-volume (P-V) systems and Telemetry Research Ltd, ... physiological signals in,freely moving laboratory animals, today ... Telemetry Research provides wireless measurement of ...
Cached Medicine News:Health News:Drug Use Increasingly Common in All Countries 2Health News:Statement by Christine James-Brown, President and CEO, Child Welfare League of America (CWLA) Re: Moratorium on Medicaid Regulations 2Health News:Medical Tactile, Inc. Announces Appointment of Denis A. O'Connor as CEO & Member of Board of Directors 2Health News: Great Doctors Produce Great Results (Healthcare Underwriters Group Mutual of Ohio Pays A Cash Dividend): -- Healthcare Underwriters Group Mutual of Ohio Pays Its First Cash Distribution to Its Insured Owners 2Health News:Millar Instruments Offers Telemetry Systems Through Worldwide Distribution Agreement with Telemetry Research Ltd 2
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "An Introduction to Medical ... November 2-3, 2015)" conference to their offering. ... comprehensive introduction to the regulations and requirements that ... be highly interactive, using real life examples and ...
(Date:9/2/2015)... , Sept. 2, 2015  Research and Markets ... the "An Introduction to the Medical Devices ... conference to their offering. This ... medical device legislation. It will explain the Directives ... Notified Bodies, how to choose one and outline ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6x789c/new_eu ) has ... Legislation (London, UK - November 16-17, 2015)" conference ... EU modules concerning Pharmacovigilance are a major departure in ... Europe . The intention of the course ... examine how they overlap and fit together and what ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... Wednesday, November 9, 2011 at 11:30 a.m. MT/1:30 p.m. ET/10:30 ... Amylin Pharmaceuticals, will provide a corporate overview. The ... Amylin,s corporate website at www.amylin.com , and a recording ...
... 2011 Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR ) ... Annual CLSA AsiaUSA Forum to be held November 7-9, 2011 ... Officer, is scheduled to present an overview of the Company ... A live webcast and subsequent archived replay of ...
Cached Medicine Technology:Questcor Pharmaceuticals to Present at CLSA's 4th Annual AsiaUSA Forum on November 7, 2011 2
Magnetic Farnsworth D15 kit Magnets move the color disks. Protects disks from fingerprints. Keeps all the disks in one place. Clear glass insures accurate color perception. Makes color testing fun....
... Farnsworth panel D15 test evaluation ... ways to arrange caps with automatic ... analysis, manual color deficiency analysis, calculation ... of age-corrected CCI, eye selection (OD, ...
... a Matching Card, three HRR symbol cards and ... child for subsequent HRR 4th Edition color testing. ... For the youngest patients, the parents can borrow ... concept of matching and become familiar with the ...
Spanish HRR/Amsler combination with Spanish and English directions for both HRR and amsler tests plus occluding glasses....
Medicine Products: